Clinical Trials Browser

Phase 3 × selinexor × Other hematologic neoplasm × Clear all

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT06613035 2024-09-25

Twice-per-weekSelinexor, 2 Days Melphalan

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute